The offering provides a substantial cash runway into 2029, reducing near-term financing risk. However, the 14.92% discount and full exercise of the over-allotment option signal aggressive capital raising. Monitor for any updates on the Nanoprimer platform pipeline and potential clinical catalysts that could offset dilution overhang.
Price Chart
Executive Summary
Nanobiotix closed a global offering of 2,218,467 ordinary shares (including ADSs) and 345,099 pre-funded warrants, raising ~$100M in gross proceeds. The offering was priced at a 14.92% discount to the VWAP, and proceeds will primarily fund the Nanoprimer platform and general corporate purposes, extending the cash runway into 2029.
Key Financial Metrics
Key Facts
- Total gross proceeds of ~$100M (€86.1M) from the global offering.
- 2,218,467 ordinary shares and 345,099 pre-funded warrants issued.
- Offering price of $38.98 per ADS (€33.60 per ordinary share), a 14.92% discount to the 3-day VWAP.
- Proceeds allocated: <10% for JNJ-1900 (NBTXR3), 50-60% for Nanoprimer and other platforms, 30-40% for general corporate purposes.
- Cash runway extended into 2029 based on current burn rate.
- Underwriters' option to purchase additional ADSs was fully exercised.
- Jefferies, TD Cowen, and Stifel acted as global coordinators and joint bookrunners.
Financial Impact
Gross proceeds of ~$100M from the offering, with a 14.92% discount to the 3-day VWAP. Dilution from 2,218,467 shares and 345,099 pre-funded warrants.
Risk Factors
- Dilution from the issuance of 2,218,467 shares and 345,099 pre-funded warrants.
- 14.92% discount to VWAP may pressure the stock in the near term.
- Proceeds allocated broadly, with management retaining discretion; execution risk on platform development.
- No specific clinical catalysts or revenue disclosed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301496 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+20 | — | — |
Oct 20, 2026 6d ago | 6-K | $25.83 | awaiting T+20 | — | $31.53 (+22.07%) |
Oct 1, 2026 25d ago | 6-K | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Oct 1, 2026 25d ago | Press Release | $25.75 | awaiting T+20 | — | $31.53 (+22.45%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▲ +11.86% | ▲ +10.38% | $31.53 (+5.34%) |
Sep 24, 2026 4w ago | 6-K | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 24, 2026 4w ago | Press Release | $33.31 $29.36 | ▼ −11.86% | ▼ −10.38% | $31.53 (−5.34%) |
Sep 22, 2026 4w ago | Press Release | $35.24 $25.83 | ▼ −26.70% | ▼ −27.39% | $31.53 (−10.53%) |
Sep 14, 2026 6w ago | 6-K | $35.73 $23.40 | ▼ −34.51% | ▼ −36.77% | $31.53 (−11.75%) |
Jul 31, 2026 12w ago | 6-K | $38.89 $40.64 | ▲ +4.50% | ▲ +3.26% | $31.53 (−18.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers